INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.14
+0.43%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$20.89
From 52W high−12.79%
Volume1.34M
Market cap$1.53B
P/E (TTM)4.3x
P/S (TTM)3.4x
Div yield—
Key dataSep 18, 2026
Open
$20.89
From 52W high
−12.79%
Volume
1.34M
Market cap
$1.53B
ValuationView details →
P/E (Fwd)
9.8x
EV/EBITDA
1.5x
P/E (TTM)
4.3x
RSI (14)
49.4
MomentumView details →
1D Return
+0.43%
YTD Return
+5.35%
SummaryUpdated Jun 1, 2026
Innoviva, Inc. (NASDAQ:INVA) is a biotechnology company founded in 1996 and headquartered in Burlingame, California. Originally incorporated as Theravance, Inc., the company changed its name to Innoviva in January 2016. The company specializes in developing and commercializing pharmaceutical products for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma. Innoviva operates through a strategic partnership model, most notably with pharmaceutical giant GlaxoSmithKline, to bring respiratory medications to market globally.
Similar companies
Latest newsMore news →
Innoviva reported Q2 2026 earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share, and compared to $0.77 per share a year ago.46d agoInnoviva Specialty Therapeutics entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in select international markets.96d ago